ClinicalTrials.gg
CompletedNCT00558285Updated Nov 30, 2012Results posted

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of indacaterol/glycopyrrolate and indacaterol in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis. Completed at 40 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. indacaterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
25th of 57
257 · median 154
Started
2007
with 5 others
Phase 2
8 of 57
none open now
Registered
9th of 57
by date
Lead sponsor
18 of 57
Novartis

Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, this one is the 25th largest by enrollment, is one of 6 that started in 2007, is one of 8 in phase 2, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About indacaterol

indacaterol: first FDA approval 2011 (ARCAPTA NEOHALER), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed. This 14 day study will investigate the effect on heart rate and cardiovascular effects to ensure the product is safe.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Indacaterol
  • QVA149
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consented male or female adults aged ≥40 years
  • Moderate to severe stable (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2006)
  • Patients who have smoking history of at least 10 pack years
  • Patients with a post-bronchodilator (FEV1) ≥30% and \<80% of the predicted normal and post-bronchodilator FEV1/Forced vital capacity (FVC) \<0.70 at Visit 1 and Visit 3

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Patients requiring long term oxygen therapy (> 15 hours a day) on a daily basis for chronic hypoxemia, or who have been hospitalized or visited an emergency room for a exacerbation in the 6 weeks prior to screening (Visit 1) or during the screening period
  • Patients who had a respiratory tract infection within 6 weeks of Visit 1 or at screening
  • Concomitant pulmonary disease, pulmonary tuberculosis (TB) (unless chest x-ray confirms no longer active) or bronchiectasis
  • Any history of asthma
  • Patients who have clinically relevant lab abnormalities / conditions such as (but not limited to) long term prednisone therapy, unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding stable atrial fibrillation [AF]), uncontrolled hypertension, narrow-angle glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment, uncontrolled hypo- and hyperthyroidism, hypokalemia, hyperadrenergic state or any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study
  • Patients with a history of cardiac failure, life threatening arrhythmias (screening Holter) and acute ischemic changes (screening )
  • Patients with a history of long syndrome or whose QTc (Fridericia method) interval measured at screening (Visit 1) is prolonged (>450 ms for males or >470 for females)
  • History of of any organ system, treated or untreated within the past 5 years
  • Uncontrolled Type I / Type II Diabetes or blood glucose outside the normal range or (HbA1c) >8.0% of total measured at Visit 1

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    indacaterol/glycopyrrolate 600/100 μg

    Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.

    Drug: indacaterol/glycopyrrolate

  • Experimental
    indacaterol/glycopyrrolate 300/100 μg

    One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.

    Drug: indacaterol/glycopyrrolate · Drug: placebo

  • Experimental
    indacaterol/glycopyrrolate 150/100 μg

    One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.

    Drug: indacaterol/glycopyrrolate · Drug: glycopyrrolate

  • Active comparator
    indacaterol 300 μg

    One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.

    Drug: indacaterol · Drug: placebo

  • Placebo comparator
    placebo

    Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.

    Drug: placebo

Interventions

  • Drugindacaterol/glycopyrrolate

    Drug pages: Indacaterol · Glycopyrrolate

    Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

    Also known as: QVA149

  • Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

    Also known as: QAB149

  • Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

  • Drugplacebo

    Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean 24 Hour Heart Rate at Day 14

    Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 14. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least square means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min post salbutamol/albuterol + error.

    Time frame: Baseline, Day 14

Secondary outcomes

  1. Change From Baseline in Mean 24 Hour Heart Rate at Day 1

    Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 1. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least squares means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.

    Time frame: Baseline, Day 1

  2. Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14

    Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline is defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Least square means are based on the analysis of covariance: response variable=center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.

    Time frame: Day 1, Day 14

  3. Trough Forced Vital Capacity (FVC) at Day 1 and Day 14

    Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FVC was defined as the mean of two measurements at 23 hours 15 minutes and the 23 hours 45 minutes post dosing. Baseline was defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Analysis of covariance: FVC parameter = center + treatment + baseline FVC + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.

    Time frame: Day 1 and Day 14

  4. Change From Baseline in QTc (Fridericia's Formula) at Day 1

    The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 1. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.

    Time frame: Baseline, Day 1

  5. Change From Baseline in QTc (Fridericia's Formula) at Day 7

    The change from baseline in QTc at 30 minutes and 2 hours post dose on day 7. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.

    Time frame: Baseline, Day 7

  6. Change From Baseline in QTc (Fridericia's Formula) at Day 14

    The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 14. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.

    Time frame: Baseline, Day 14

07

Results

Posted Nov 22, 2012

Participant flow

Participant flow — Overall Study
MilestoneIndacaterol/Glycopyrrolate 600 μg/100 μgIndacaterol/Glycopyrrolate 300 μg/100 μgIndacaterol/Glycopyrrolate 150 μg/100 μgIndacaterol 300 μgPlacebo
Started5051515253
Safety: received study drug4951515153
Completed4448464849
Not completed63544
Withdrew: Adverse event11412
Withdrew: Abnormal test procedure result(s)10000
Withdrew: Subject withdrew consent20111
Withdrew: Lost to follow-up11000
Withdrew: Administrative problems00011
Withdrew: Protocol deviation11010

Outcome measures

PrimaryChange From Baseline in Mean 24 Hour Heart Rate at Day 14

Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 14. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least square means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min post salbutamol/albuterol + error.

Time frame:
Baseline, Day 14
Reported as:
Least squares mean · beats per minute
Change From Baseline in Mean 24 Hour Heart Rate at Day 14
beats per minuteIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Change From Baseline in Mean 24 Hour Heart Rate at Day 14-0.113 ± 0.99670.787 ± 0.8975-0.230 ± 0.95670.240 ± 0.93730.170 ± 0.8760
SecondaryChange From Baseline in Mean 24 Hour Heart Rate at Day 1

Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 1. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least squares means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.

Time frame:
Baseline, Day 1
Reported as:
Least squares mean · beats per minute
Change From Baseline in Mean 24 Hour Heart Rate at Day 1
beats per minuteIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Change From Baseline in Mean 24 Hour Heart Rate at Day 1-2.877 ± 0.8790-2.770 ± 0.8244-0.547 ± 0.8208-1.849 ± 0.8211-0.329 ± 0.8181
SecondaryTrough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14

Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline is defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Least square means are based on the analysis of covariance: response variable=center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.

Time frame:
Day 1, Day 14
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14
LitersIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Day 11.59 ± 0.0241.51 ± 0.0231.50 ± 0.0221.44 ± 0.0231.27 ± 0.022
Day 141.61 ± 0.0271.52 ± 0.0251.50 ± 0.0261.46 ± 0.0251.31 ± 0.024
SecondaryTrough Forced Vital Capacity (FVC) at Day 1 and Day 14

Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FVC was defined as the mean of two measurements at 23 hours 15 minutes and the 23 hours 45 minutes post dosing. Baseline was defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Analysis of covariance: FVC parameter = center + treatment + baseline FVC + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.

Time frame:
Day 1 and Day 14
Reported as:
Least squares mean · Liters
Trough Forced Vital Capacity (FVC) at Day 1 and Day 14
LitersIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Day 13.151 ± 0.04373.029 ± 0.04213.000 ± 0.04032.924 ± 0.04192.634 ± 0.0402
Day 14 (n=42, 45, 44, 48, 47)3.134 ± 0.04693.042 ± 0.04462.952 ± 0.04552.901 ± 0.04422.726 ± 0.0424
SecondaryChange From Baseline in QTc (Fridericia's Formula) at Day 1

The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 1. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.

Time frame:
Baseline, Day 1
Reported as:
Least squares mean · milliseconds
Change From Baseline in QTc (Fridericia's Formula) at Day 1
millisecondsIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
30 minutes1.6 ± 1.581.2 ± 1.481.4 ± 1.503.1 ± 1.47-1.6 ± 1.44
4 hours2.8 ± 1.670.5 ± 1.562.4 ± 1.581.1 ± 1.60-2.3 ± 1.52
23 hours 45 minutes2.7 ± 1.77-1.7 ± 1.66-0.1 ± 1.67-2.1 ± 1.71-2.3 ± 1.62
SecondaryChange From Baseline in QTc (Fridericia's Formula) at Day 7

The change from baseline in QTc at 30 minutes and 2 hours post dose on day 7. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.

Time frame:
Baseline, Day 7
Reported as:
Least squares mean · milliseconds
Change From Baseline in QTc (Fridericia's Formula) at Day 7
millisecondsIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
30 minutes4.1 ± 1.91-0.9 ± 1.740.5 ± 1.78-1.3 ± 1.79-2.2 ± 1.70
2 hours2.6 ± 2.17-1.2 ± 1.981.6 ± 2.02-1.6 ± 2.00-2.8 ± 1.94
SecondaryChange From Baseline in QTc (Fridericia's Formula) at Day 14

The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 14. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.

Time frame:
Baseline, Day 14
Reported as:
Least squares mean · milliseconds
Change From Baseline in QTc (Fridericia's Formula) at Day 14
millisecondsIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
30 minutes2.4 ± 1.79-0.6 ± 1.641.6 ± 1.70-1.2 ± 1.690.2 ± 1.62
4 hours2.8 ± 1.90-0.1 ± 1.763.1 ± 1.85-2.6 ± 1.81-0.1 ± 1.73
23 hours 45 minutes0.5 ± 1.94-2.9 ± 1.810.4 ± 1.95-3.6 ± 1.88-1.6 ± 1.77

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Indacaterol/Glycopyrrolate 600/100 μg—2/49 (4.1%)5/49 (10.2%)
Indacaterol/Glycopyrrolate 300/100 μg—0/51 (0%)6/51 (11.8%)
Indacaterol/Glycopyrrolate 150/100 μg—2/51 (3.9%)10/51 (19.6%)
Indacaterol 300 μg—0/51 (0%)7/51 (13.7%)
Placebo—1/53 (1.9%)4/53 (7.5%)
Most frequent serious events
Most frequent serious events
EventIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Atrial fibrillationCardiac disorders1/490/510/510/510/53
Blood potassium increasedInvestigations1/490/510/510/510/53
AnaemiaBlood and lymphatic system disorders0/490/511/510/510/53
Ventricular tachycardiaCardiac disorders0/490/511/510/510/53
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/490/510/510/511/53
Most frequent other events
Most frequent other events
EventIndacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/492/515/511/511/53
Dry mouthGastrointestinal disorders3/491/513/510/510/53
CoughRespiratory, thoracic and mediastinal disorders3/492/513/512/511/53
HeadacheNervous system disorders2/491/512/513/511/53
HypertensionVascular disorders0/493/511/511/511/53

Baseline characteristics

Age Continuous
Age Continuous(years)Indacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlaceboTotal
Mean65.7 ± 9.3463.7 ± 8.9460.9 ± 8.5864.5 ± 9.7564.3 ± 8.9563.8 ± 9.19
Sex: Female, Male
Sex: Female, Male(Participants)Indacaterol/Glycopyrrolate 600/100 μgIndacaterol/Glycopyrrolate 300/100 μgIndacaterol/Glycopyrrolate 150/100 μgIndacaterol 300 μgPlaceboTotal
Female111015101460
Male3841364139195
08

Study locations

40 sites
  • Novartis Investigator Site
    Adelaide, Australia
  • Novartis Investigator Site
    Clayton, Australia
  • Novartis Investigator Site
    Daw Park, Australia
  • Novartis Investigator site
    Heidelberg, Australia
  • Novartis Investigator Site
    Nedlands, Australia
  • Novartis Investigator Site
    Brussels, Belgium
  • Novartis Investigator Site
    Jambes, Belgium
  • Novartis Investigator Site
    Jette, Belgium
  • Novartis Investigator site
    Liege, Belgium
  • Novartis Investigator Site
    Oostende, Belgium
  • Novartis Investigator Site
    Mississauga, Canada
  • Novartis Investigator Site
    Newmarket, Canada
  • Novartis Investigator Site
    Ottawa, Canada
  • Novartis Investigator Site
    Pointe-Claire, Canada
  • Novartis Investigator Site
    Quebec, Canada
  • Novartis Investigator Site
    Sainte-Foy, Canada
  • Novartis Investigator Site
    Ambroise, France
  • Novartis Investigator Site
    Lille, France
  • Novartis Investigator Site
    Marseille, France
  • Novartis investigator site
    Martigues, France
  • Novartis Investigator Site
    Nantes, France
  • Novartis Investigator site
    Nice, France
  • Novartis Investigator Site
    Perpignan, France
  • Novartis Investigator Site
    Berlin, Germany
  • Novartis Investigator Site
    Dortmund, Germany
  • Novartis Investigator Site
    Erfurt, Germany
  • Novartis Investigator Site
    Hannover, Germany
  • Novartis Investigator Site
    Mainz, Germany
  • Novartis Investigator Site
    Marburg, Germany
  • Novartis Investigator Site
    Firenze, Italy
  • Novartis Investigator site
    Modena, Italy
  • Novartis Investigator Site
    Trieste, Italy
  • Novartis Investigator Site
    Badalona, Spain
  • Novartis Investigator Site
    Baracaldo, Spain
  • Novartis Investigator Site
    Caceres, Spain
  • Novartis Investigator Site
    Centelles, Spain
  • Novartis Investigator Site
    Mataro, Spain
  • Novartis Investigator Site
    Valencia, Spain
  • Novartis Investigator Site
    Istanbul, Turkey
  • Novartis Investigator Site
    Izmir, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2007
First posted
Nov 14, 2007
Start
Nov 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Nov 22, 2012
Last update
Nov 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00558285
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Nov 14, 2007
Start date
Nov 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Nov 22, 2012
Last update
Nov 30, 2012

Study contacts

Novartis Pharma AG
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indacaterol · Glycopyrrolate

Start the discussion